Cover Image
市場調查報告書

生物武器國防市場分析:各產品 (炭疽菌,天花,肉毒桿菌中毒,放射線/核,伊波拉,出血熱) 、各市場區隔的預測

Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020

出版商 Grand View Research, Inc. 商品編碼 342329
出版日期 內容資訊 英文 80 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物武器國防市場分析:各產品 (炭疽菌,天花,肉毒桿菌中毒,放射線/核,伊波拉,出血熱) 、各市場區隔的預測 Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020
出版日期: 2015年01月01日 內容資訊: 英文 80 Pages
簡介

全球生物武器國防市場預測將在2020年前達到133億3千萬美元的規模。生物恐怖行動的威脅,疾病的蔓延,加上生物科技領域研究開發投資的增加,預測都將推動市場的成長。

本報告提供全球生物武器國防市場相關調查分析,提供您各產品,各地區的預測,加上主要企業相關的系統性資訊。

第1章 摘要整理

第2章 生物武器國防工業預測

  • 市場區隔
  • 市場規模與成長預測
  • 市場動態
    • 推動市場要素分析
    • 阻礙市場要素分析
  • 優先的主要機會
  • PESTEL分析
  • 市場方案:各類型

第3章 生物武器國防的各產品預測

  • 各產品
  • 炭疽菌
  • 天花
  • 肉毒桿菌中毒
  • 放射線/核防禦
  • 其他

第4章 生物武器國防的各地區預測

  • 各地區
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
  • 亞太地區
    • 日本
    • 中國
  • 其他

第5章 競爭情形

  • 企業簡介 (企業概要,財務實際成果,產品基準,策略性構想)
    • Xoma Corporation
    • PharmAthene
    • Emergent Biosolutions
    • Dynavax Technologies Inc.
    • SIGA Technologies
    • Elusys Therapeutics
    • Ichor Medical Systems Inc.
    • DynPort Vaccine Company LLC
    • Cleveland BioLabs, Inc.
    • Bavarian Nordic
    • Achaogen
    • Nanotherapeutics, Inc.
    • Alnylam Pharmaceuticals

第6章 調查手法和範圍

圖表

目錄

Global biodefense market is expected to reach USD 13.33 billion by 2020. Growing R&D investments in the field of biotechnology coupled with increasing threat of bioterrorism and disease outbreaks is expected to drive market growth during the forecast period. Furthermore, presence of favorable government initiatives for instance the Emergency Use Authorization (EUA) is expected to boost market growth. This provision allows products to be marketed without an FDA approval in an emergency. Initiatives undertaken by the governments of developing nations for strengthening their respective biodefense product portfolio is expected to fuel future market growth.

Biodefense against anthrax accounted for the largest market share owing to its inclusion in the class A highest priority pathogen category. This classification has resulted in the presence of extensive R&D investments aimed at new product development for strengthening national stockpiles. The global biodefense against anthrax was valued at over USD 2.0 billion in 2013.

Further key findings from the study suggest:

North American was the most revenue generating region in 2013. Majority of the funding programs are organized by the U.S. based government and private establishments. Moreover, these establishments cater to procurement needs of foreign markets.

The market is majorly governed by the initiatives undertaken in the U.S. The country is the largest revenue contributor and is expected to maintain its market position throughout the forecast period. Moreover, funding received by manufacturers under projects such as BioShield is expected to significantly boost demand over the next six years.

Developed European countries such as Germany and the UK have designated funding policies in place pertaining to biodefense. In Switzerland, there is no set biodefense definition but the NBC (nuclear, biological, chemical) protection and research is carried out in Spiez Laboratory of Federal office for Civil Protection, within the Federal Department of Defense. A total of 12 civilian facilities operate under the Swiss biodefense program.

Key players of this market include Emergent BioSolutions, SIGA Technologies, Xoma Corporation and PharmAthene.

Mergers and acquisitions and participating in government tenders are two key sustainability strategies adopted by market players. For instance, in December, 2014, Emergent BioSolutions announced that it had acquired the EV-035 series of molecules from Evolva Holding SA. The acquisition will further strengthen the company's biodefense line of products.

For the purpose of this study, Grand View Research has segmented the global biodefense market on the basis of product and region:

Global Biodefense Product Outlook (Revenue, USD Million, 2012 - 2020)

  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/Nuclear defense
  • Others

Biodefense Regional Outlook (Revenue, USD Million, 2012 - 2020)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • Japan
    • China
  • RoW
    • Brazil

Table of Contents

Chapter 1: Executive Summary

Chapter 2: Biodefense Industry Outlook

  • 2.1. Market Segmentation
  • 2.2. Market size and growth prospects
  • 2.3. Biodefense-Market dynamics
    • 2.3.1. Market driver analysis
      • 2.3.1.1. Presence of favorable government initiatives
      • 2.3.1.1.1. Emergency Use Authorization of Medical Products
      • 2.3.1.1.2. Project BioShield Act
    • 2.3.2. Market Restraint Analysis
      • 2.3.2.1. Low market penetration in developing and underdeveloped countries
  • 2.4. Key Opportunities Prioritized
  • 2.6. Biodefense-PESTEL analysis
  • 2.7. Market scenario by type
    • 2.7.1. Biological Defense
    • 2.7.2. Chemical Defense
      • 2.7.2.1. Chemical defense: Product pipeline
    • 2.7.3. Nuclear/Radiological Defense
      • 2.7.3.1. Nuclear/radiological defense: Product pipeline analysis

Chapter 3: Biodefense Product Outlook

  • 3.1. Biodefense market share by product, 2013 & 2020
  • 3.2. Anthrax
    • 3.2.1. Biodefense against anthrax market, 2012-2020(USD Million)
  • 3.3. Smallpox
    • 3.3.1. Biodefense against smallpox market, 2012-2020(USD Million)
  • 3.4. Botulism
    • 3.4.1. Biodefense against botulism market, 2012-2020(USD Million)
  • 3.5. Radiation/ nuclear defense
    • 3.5.1. Biodefense against radiation/nuclear defense market, 2012-2020(USD Million)
  • 3.6. Others
    • 3.6.1. Biodefense against other threats market, 2012-2020(USD Million)

Chapter 4: Biodefense Regional Outlook

  • 4.1. Biodefense market share by region, 2013 & 2020
  • 4.2. North America
    • 4.2.1. North America biodefense market, 2012-2020(USD Million)
    • 4.2.2. U.S. biodefense market, 2012-2020(USD Million)
    • 4.2.3. U.S. biodefense market,2012-2020(USD Million)
      • 4.2.3.1. U.S. biodefense market, by scenario, 2012-2020(USD Million)
    • 4.2.4. U.S. biodefense market, by source, 2012-2020(USD Million)
      • 4.2.4.1. Federal Agencies
      • 4.2.4.1.1. BioShield Act
      • 4.2.4.1.2. Department of Health and Human Services(HHS)
      • 4.2.4.1.3. Department of Defense(DoD)
      • 4.2.4.1.4. Department of Homeland Security
      • 4.2.4.1.5. Department of Agriculture
      • 4.2.4.1.6. Environmental Protection Agency
      • 4.2.4.1.7. Department of Commerce
      • 4.2.4.2. Other Agencies
    • 4.2.5. Canada biodefense market, 2012-2020(USD Million)
  • 4.3. Europe
    • 4.3.1. Europe biodefense market, 2012-2020(USD Million)
    • 4.3.2. Germany biodefense market, by product,2012-2020(USD Million)
    • 4.3.3. Germany biodefense market, 2012-2020(USD Million)
    • 4.3.4. UK biodefense market, by product, 2012-2020(USD Million)
    • 4.3.5. UK biodefense market, 2012-2020(USD Million)
  • 4.4. Asia Pacific
    • 4.4.1. Asia Pacific biodefense market, 2012-2020(USD Million)
    • 4.4.2. Japan biodefense market, 2012-2020(USD Million)
    • 4.4.3. Japan biodefense market, 2012-2020(USD Million)
    • 4.4.4. China biodefense market, 2012-2020(USD Million)
  • 4.5. RoW
    • 4.5.1. RoW biodefense market, 2012-2020(USD Million)

Chapter 5: Competitive Landscape

  • 5.1. Xoma Corporation
    • 5.1.1. Company Overview
    • 5.1.2. Financial Performance
    • 5.1.3. Product Benchmarking
    • 5.1.4. Strategic Initiatives
  • 5.2. PharmAthene
    • 5.2.1. Company Overview
    • 5.2.2. Financial Performance
    • 5.2.3. Product Benchmarking
    • 5.2.4. Strategic Initiatives
  • 5.3. Emergent Biosolutions
    • 5.3.1. Company Overview
    • 5.3.2. Financial Performance
    • 5.3.3. Product Benchmarking
    • 5.3.4. Strategic Initiatives
  • 5.4. Dynavax Technologies Inc.
    • 5.4.1. Company Overview
    • 5.4.2. Financial Performance
    • 5.4.3. Product Benchmarking
    • 5.4.4. Strategic Initiatives
  • 5.5. SIGA Technologies
    • 5.5.1. Company Overview
    • 5.5.2. Financial Performance
    • 5.5.3. Product Benchmarking
    • 5.5.4. Strategic Initiatives
  • 5.6. Elusys Therapeutics
    • 5.6.1. Company Overview
    • 5.6.2. Financial Performance
    • 5.6.3. Product Benchmarking
    • 5.6.4. Strategic Initiatives
  • 5.7. Ichor Medical Systems Inc.
    • 5.7.1. Company Overview
    • 5.7.2. Financial Performance
    • 5.7.3. Product Benchmarking
    • 5.7.4. Strategic Initiatives
  • 5.8. DynPort Vaccine Company LLC
    • 5.8.1. Company Overview
    • 5.8.2. Financial Performance
    • 5.8.3. Product Benchmarking
    • 5.8.4. Strategic Initiatives
  • 5.9. Cleveland BioLabs, Inc.
    • 5.9.1. Company Overview
    • 5.9.2. Financial Performance
    • 5.9.3. Product Benchmarking
    • 5.9.4. Strategic Initiatives
  • 5.10. Bavarian Nordic
    • 5.10.1. Company Overview
    • 5.10.2. Financial Performance
    • 5.10.3. Product Benchmarking
    • 5.10.4. Strategic Initiatives
  • 5.11. Achaogen
    • 5.11.1. Company Overview
    • 5.11.2. Financial Performance
    • 5.11.3. Product Benchmarking
    • 5.11.4. Strategic Initiatives
  • 5.12. Nanotherapeutics, Inc.
    • 5.12.1. Company Overview
    • 5.12.2. Financial Performance
    • 5.12.3. Product Benchmarking
    • 5.12.4. Strategic Initiatives
  • 5.13. Alnylam Pharmaceuticals
    • 5.13.1. Company Overview
    • 5.13.2. Financial Performance
    • 5.13.3. Product Benchmarking
  • 5.14. Major list of biodefense contracts, by market player

Chapter 6: Methodology and Scope

  • 6.1. Research Methodology
  • 6.2. Research Scope & Assumptions
  • 6.3. List of Data Sources

List of Tables

  • TABLE 1: Biodefense Market - Industry Summary & Critical Success Factors (CSFs)
  • TABLE 2: Biodefense market, by region, 2012 - 2020 (USD Million)
  • TABLE 3: U.S. biodefense market, by product, 2012 - 2020 (USD million)
  • TABLE 4: Biodefense - Key market driver analysis
  • TABLE 5: Biodefense - Key market restraint analysis
  • TABLE 6: Biological defense: Product pipeline
  • TABLE 7: List of pipeline products: Anthrax
  • TABLE 8: List of pipeline products: Smallpox
  • TABLE 9: List of pipeline products: Botulism
  • TABLE 10: List of pipeline products: Radiation/nuclear defense
  • TABLE 11: List of pipeline products: Other threats
  • TABLE 12: U.S. biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 13: U.S. biodefense market, by scenario, 2012 - 2020 (USD Million)
  • TABLE 14: U.S. biodefense market, by source, 2012 - 2020 (USD Million)
  • TABLE 15: Programs under HHS:
  • TABLE 16: Programs under DoD:
  • TABLE 17: Programs under department of homeland security
  • TABLE 18: Programs under department of agriculture
  • TABLE 19: Canada biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 20: Germany biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 21: Biodefense program licensed manufacturing sites in the UK
  • TABLE 22: UK biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 23: Japan biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 24: China biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 25: RoW biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 26: Major list of biodefense contracts, by market player

List of Figures

  • FIG. 1: Biodefense: Market segmentation
  • FIG. 2: Global biodefense market, 2012 - 2020 (USD Million)
  • FIG. 3: Biodefense: Market dynamics
  • FIG. 4: Key opportunities prioritized
  • FIG. 5: Biodefense market - Porter's analysis
  • FIG. 6: Biodefense market - PESTEL analysis
  • FIG. 7: Biodefense market share by product, 2013 & 2020
  • FIG. 8: Global anthrax biodefense market, 2012 - 2020 (USD Million)
  • FIG. 9: Global smallpox biodefense market, 2012 - 2020 (USD Million)
  • FIG. 10: Global botulism biodefense market, 2012 - 2020 (USD Million)
  • FIG. 11: Global radiation/nuclear defense market, 2012 - 2020 (USD Million)
  • FIG. 12: Global biodefense market for other threats, 2012 - 2020 (USD Million)
  • FIG. 13: Biodefense market share by region, 2013 & 2020
  • FIG. 14: North America biodefense market , 2012 - 2020 (USD Million)
  • FIG. 15: U.S. biodefense market , 2012 - 2020 (USD Million)
  • FIG. 16: Canada biodefense market , 2012 - 2020 (USD Million)
  • FIG. 17: Europe biodefense market , 2012 - 2020 (USD Million)
  • FIG. 18: Germany biodefense market , 2012 - 2020 (USD Million)
  • FIG. 19: UK biodefense market , 2012 - 2020 (USD Million)
  • FIG. 20: Asia Pacific biodefense market , 2012 - 2020 (USD Million)
  • FIG. 21: Japan biodefense market , 2012 - 2020 (USD Million)
  • FIG. 22: China biodefense market , 2012 - 2020 (USD Million)
  • FIG. 23: RoW biodefense market , 2012 - 2020 (USD Million)
Back to Top